Healthcare Associated Infections (HAI) Treatment Market

HAIs are a major cause of mortality and morbidity on a worldwide scale. Each year HAIs lead to thousands of deaths. A majority of HAIs include conditions such as urinary tract infections, surgical site infections, bloodstream infections, gastroenteritis, and pneumonia. The overall HAI treatment market can be classified on the basis of devices and pharmaceuticals used for HAI treatment. The major pharmaceuticals used in HAI treatment are viral pharmaceuticals, bacterial pharmaceuticals, and fungal pharmaceuticals. The major drug classes used in the pharmaceuticals segment are B-Lactam Antibiotics, cephalosporins, quinolones, glycopeptides, lincosamides, polypeptides, carbapenems, lipopeptides, penicillins, macrolides, tuberculosis, etracyclines, sulfonamides, and other such formulations. The medical devices segment can be further categorized into catheters and ventilation devices and in-line sterile IV filtration. The U.S. is the largest market for HAI treatment pharmaceuticals and devices. In the U.S., each year more than 1.5 million patients contract HAI. Recently Partners for Patients had introduced a USD 500 million grant to help hospitals and other healthcare providers to reduce HAIs in the U.S. it is expected that if successful, this program will save USD 50 billion of U.S. Medicare over the next ten years. The other markets for HAI treatment devices and pharmaceuticals are Asia-Pacific, Europe, and the Rest of the World. Some of the major players of this market include companies such as Merck, Johnson & Johnson, GlaxoSmithKline, Sharklet Technologies, Ondine Biomedical and some others.

Infections that occur whilst staying in a healthcare institution, such as a nursing home, rehabilitation centre, or hospital, are known as healthcare-associated infections (HAIs). Let's take the scenario of someone who just undergone surgery. If the surgical site starts to look red, swell, as well as hurt, one probably have had an infection there. It is a HAI if the infection originated from the hospital and did not exist prior to the operation.

Hospital sanitation and sterilization procedures are a growing source of worry. Nosocomial infections are those that manifest within 48 hours after hospital admission, 3 days after release, or 30 days following a surgery. One in ten hospitalized patients suffer from them, which is likely to drive revenue-generation opportunities in healthcare associated infections (HAI) treatment industry. Nosocomial infections have a significant impact on mortality, morbidity, and substantially increased financial burden.

Adult as well as paediatric patients can get healthcare-associated infections. Urinary tract infections are the most prevalent healthcare-associated infections in adults, whereas bloodstream infections, pneumonia, and UTIs represent the most prevalent infections in children. Healthcare-associated infections are more common amongst paediatric patients under the age of 1 year, children in the PICU or NICU, and infants with low birth weights (1000g).

Both cleaning as well as bacterial control cannot be accomplished using conventional cleaning techniques. New methods including antimicrobial surfaces, automated dispersion systems, steam, and disinfectants are replacing earlier concepts as a result of technological improvements. These are all recent developments in the healthcare associated infections (HAI) treatment. A number of technologies that attempt to lower the risk of HAIs been developed in the recent years. These methods have the potential to dramatically transform patient care. Several new techniques for preventing the spread of pathogens comprise purification of the environment.

The use of antimicrobial surfaces, no-touch technology, and novel disinfectants and delivery systems is growing in hospitals. For instance, the Joe DiMaggio Children's Hospital in the US started testing technologies based on intelligent observation in January 2021. The alternate approach makes use of near-field magnetic induction or NFMI technology. It checks to see if medical professionals are washing or sterilizing their hands properly and on time. In comparison to earlier systems that depend on wireless radio-frequency identification (RFID) technology, NFMI has more precision and accuracy.

Hospitals that are congested and lowered immunity levels among people are some of the numerous variables that are pushing people into the market. In addition, the unforeseen development of infectious illnesses, the scarcity of medical equipment, and the emergence of bacterial resistance to conventional medicines are all projected to drive growth of the market.